341 A phase Ib expansion cohort of pixatimod plus nivolumab in previously treated, microsatellite stable metastatic colorectal cancer (MSS mCRC)

• Matthew Burge,
• David Goldstein,
• Andrew Haydon,
• Nick Pavlakis,
• Michael Brown,
• Charlotte Lemech,
• Edward Hammond,
• Darryn Bampton,
• Keith Dredge,
• Nigel Waterhouse,
• Amanda Stanley,
• Lucie Leveque-ElMouttie,
• Grace Chojnowski,
• Andrew Clouson

Affiliations

Matthew Burge

11 Department of Medical Oncology, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia

David Goldstein

Department of Otolaryngology and Head and Neck Surgery, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada

Andrew Haydon

Department of Medical Oncology, Alfred Hospital, Melbourne, Victoria, Australia

Nick Pavlakis

Faculty of Medicine, The University of Sydney, Sydney, New South Wales, Australia

Michael Brown

7Royal Adelaide Hospital, Adelaide, Australia

Charlotte Lemech

Aff5 Scientia Clinical Research Sydney Australia

Edward Hammond

Aff1 Zucero Therapeutics 4076 Brisbane QLD Australia

Darryn Bampton

Aff1 Zucero Therapeutics 4076 Brisbane QLD Australia

Keith Dredge

Aff1 Zucero Therapeutics 4076 Brisbane QLD Australia

Nigel Waterhouse

Immunity, Infection and Inflammation Program, Mater Medical Research Institute and The University of Queensland, Mater Health Services, South Brisbane, Queensland, Australia

Amanda Stanley

3QIMR Berghofer, Brisbane, Australia

Lucie Leveque-ElMouttie

3QIMR Berghofer, Brisbane, Australia

Grace Chojnowski

3QIMR Berghofer, Brisbane, Australia

Andrew Clouson

3Royal Brisbane and Women’s Hospital, Brisbane, Australia